NCT05357417: Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases

NCT05357417
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have been previously treated with at least one anthracycline and one taxane (as neoadjuvant therapy, adjuvant therapy, palliative therapy, or both)
Exclusions: Patients with leptomeningeal metastases that require immediate local therapy
https://ClinicalTrials.gov/show/NCT05357417

Comments are closed.

Up ↑